|
Good News for Non-Responders to HCV Combination Therapy
A Phase 3 trial evaluating ZADAXIN® (thymalfasin) as a potential third component for Hepatitis C traditional combination therapy has just been completed. Although the data is currently being analyzed and won't be available until later in the year, the lead...
Purer, Less Costly Interferon for Hepatitis C and B Treatment
The Taiwan-based biopharmaceutical company PharmaEssentia Corp. is testing P1101, its third-generation PEG-interferon-alpha drug candidate. Because it is a longer-lasting, purer interferon that is less costly to produce, P1101 could enhance the treatment options for Hepatitis C and B....
New Technology May Help Treat Hepatitis
While pharmaceutical companies are racing to find safer, more effective treatments for viral Hepatitis C and B, physicists from Arizona have a unique perspective on accomplishing the same goal. Learn how these scientists believe the virus could be rendered harmelss...
|
|
|
University of Iowa Family Practice Handbook, 3rd Edition, Chapter 4
Gastroenterology: Alcoholic Liver Disease, Liver Failure and Chronic Liver
Disease
Peter P. Toth, M.D., Ph.D.
Department of Family Medicine
University of Iowa
Peer Review Status: Externally Peer Reviewed by Mosby
Alcoholic Liver Disease
- Cause is chronic alcohol ingestion.
- See chronic liver disease below for symptoms and signs.
- Clinically resembles hepatitis and progresses to cirrhosis.
- Must abstain from alcohol.
- See chronic liver disease below for manifestations and treatment.
Liver Failure and Chronic Liver Disease
- Cirrhosis
Cirrhosis is a diffuse process consisting of islands of regenerated liver
surrounded by dense fibrosis that occurs after a protracted insult (such as
alcohol, chronic active hepatitis).
- Symptoms of Cirrhosis
Weight loss, malnutrition, fatigue, easy bruising (caused by reduced levels
of factors II, VII, IX, and X), jaundice, encephalopathy, pruritus, edema,
and ascites. The patient may also have GI bleeding from esophageal varices
(caused by portal hypertension) or coma. Look for fetor hepaticus, asterixis,
and hyperreflexia. GI bleeding is a common cause of encephalopathy and coma
in liver failure patients because of the large gastrointestinal protein load.
- Laboratory Evaluation
Laboratory evaluation may show normal liver enzymes in end-stage disease because
of the small amount of residual hepatic tissue. These patients will usually
have low serum levels of total protein and albumin. Anemia and thrombocytopenia
may also be present. Blood ammonia levels may be elevated, but these correlate
poorly with clinical manifestations of coma. Electrolyte abnormalities include
hyponatremia, hypokalemia, and water overload (see also sections on these
topics). There may also be concomitant acidosis or alkalosis.
- Treatment
Consists in removal of the offending agent (such as alcohol).
- Acute treatment (for coma or encephalopathy).
- Clean bowels with enemas.
- Neomycin 4 to 6 g PO QD in divided doses to reduce bacterial toxins.
May be given via NG tube.
- Lactulose 30 to 45 g PO TID to produce two or three loose stools
per day.
- Limit total protein intake to 20 to 40 g/day.
- Vitamin K 5 to 10 mg/day for 2 or 3 days may help coagulation.
- Potassium supplements may be used for hypokalemia.
- Potassium-sparing diuretics such as spironolactone 100 to 300 mg/day
divided into 2 or 3 doses will reduce ascites without decreasing potassium.
Hydrochlorothiazide or furosemide may be added to this regimen if
needed (see section on ascites below).
- Chronic treatment. Chronic treatment includes the prevention of coma
or encephalopathy with the measures outlined above as well as chronic
management of electrolyte disorders.
- Watch for spontaneous peritonitis, which can occur with
ascites (see section on ascites).
- Acetaminophen toxicity is common in this population with doses that
are generally considered nontoxic.
table Of Contents
|
|
